Kura Oncology, Inc. (KURA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$13.25+0.76%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Kura Oncology is advancing its cancer drug ziftomenib with strong trial results. The company expects to recognize $45 million to $55 million in collaboration revenue in 2026. Recent positive news and FDA approval support growth. The stock price is up over 40% in 63 days, showing renewed investor interest.
Kura Oncology remains unprofitable with negative EPS expected through 2027. Revenue is small, guided at only $5.8 million for 2026. The company has missed earnings multiple times recently. The biotech sector is risky and the stock is volatile.
The market prices Kura about 30% below our fair value near $17, reflecting skepticism on growth and profitability. Our fair value is also 29% below the Street median, indicating cautious optimism. We see upside if drug development and collaboration revenue targets are met.
Breaks if: collaboration revenue falls below $45M in 2026
Breaks if: revenue falls below $5.8M in 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. KURA is focused on commercializing its products and advancing its pipeline, but it faces risks from market conditions and execution challenges.
The market currently prices in a low level of fragility, indicating that it does not expect significant disruptions. However, KURA's valuation shows a durable premium compared to its peers, reflecting higher expectations for its future performance.
KURA's recent financial performance has been neutral, with a notable earnings beat but overall momentum declining. The company remains focused on key management priorities, although the mixed status of its clinical developments may pose challenges.
The long-term thesis hinges on KURA's ability to maintain growth in its commercial products and successfully advance its clinical trials. Additionally, broader sector performance and economic conditions will significantly impact KURA's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports the thesis. New data on ziftomenib resistance broadens treatment opportunities. There is confidence in the launch progress of KOMZIFTI. No new threats have emerged.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: ziftomenib fails to gain broader clinical adoption or trial results weaken
In the next 1 to 3 years, KURA's performance will depend on its execution and external market factors. Not investment advice.